Company & Sponsor Intelligence

M.D. Anderson Cancer Center

Evidence-linked intelligence derived from the current NeuroRisk clinical research corpus. Coverage reflects indexed source data and is not a claim of complete company activity.

Request enterprise analysis →

Indexed trials4

Recruiting3

Completed0

Countries1

Therapeutic footprint

epilepsyother_psychiatrypain_neuropathy

Indexed studies

NCT04553757Seizure Control as a New Metric in Assessing Efficacy of Tumor Treatment in Patients With Low Grade Glioma
epilepsy · United StatesACTIVE_NOT_RECRUITING

NCT05431595Managing Agitated Delirium With Neuroleptics and Anti-Epileptics as a Neuroleptic Sparing Strategy
epilepsy · United StatesPHASE2, PHASE3

NCT04135326Transcranial Direct Current Stimulation in Reducing Pain in Cancer Patients With Chemotherapy Induced Peripheral Neuropathy
pain_neuropathy · United StatesEARLY_PHASE1

NCT03743649Haloperidol and Lorazepam in Controlling Symptoms of Persistent Agitated Delirium in Patients With Advanced Cancer Undergoing Palliative Care
other_psychiatry · United StatesPHASE2, PHASE3

Intelligence layer updated: 2026-10-29 06:17:44.639239+00:00

Enterprise intelligence

Compare sponsor activity, recruiting momentum, therapeutic exposure, geography and connected research signals across the neuroscience ecosystem.

Request comparative intelligence →